Our goal is to provide doctors with a tool to remove harmful components from the bloodstream to treat blood-borne diseases.

Keep In Touch

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood-borne diseases. The company’s initial targets are Sepsis, Leukaemia and Malaria. Located in the Translation and Innovation Hub in White City, the company is preparing for first-in-man trials in 2020.

Our multidisciplinary team has experience across various fields of science and technology development.

 

A Great Start to 2020

A Great Start to 2020
January 16, 2020

If you missed it, before Christmas, we announced that Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, had been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35

MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35
December 19, 2019

Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.